Zobrazeno 1 - 10
of 57
pro vyhledávání: '"G G, Neznamov"'
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 2, Pp 57-63 (2018)
The results of the quality of life (QoL) changes study during fabomotizole treatment in patients with anxiety disorders are presented. The QoL indexes measured with WHOQOL-BREF questionnaire in patients with anxiety disorders are significantly decrea
Externí odkaz:
https://doaj.org/article/edc35991eb4342ebbab107373e4186c9
Autor:
T S Syunyakov, G G Neznamov
Publikováno v:
Терапевтический архив, Vol 88, Iss 8, Pp 73-86 (2016)
Aim. To summarize the previously published results of a multicenter randomized clinical research phase III study trial of afobazole (INN: fabomotizole) versus diazepam in the treatment of patients with generalized anxiety disorder (GAD) and adjustmen
Externí odkaz:
https://doaj.org/article/d5661be1ff394084a6e67f0b8d7bc4e5
Publikováno v:
Фармакокинетика и Фармакодинамика, Vol 0, Iss 1, Pp 44-51 (2014)
The effect of single and multiple modes of administration pantogam (pantokaltsina) and bemitil (metaprot) on the dynamics of nootropic specific and nonspecific behavioral effects of anxiolytic drugs and their possible association with NMDA- and benzo
Externí odkaz:
https://doaj.org/article/62ac6bef769d4c108a16e422424a9932
Publikováno v:
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 120(2)
To evaluate the psychotropic specific spectrum activity of the novel peptide drug dilept and to find its effective doses in patients with schizotypal disorder.The effects of dilept were studied in 25 patients (33.4±10.0 years old) with schizotypal d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35f32ac44b200121cf44a4396f6fd059
https://pubmed.ncbi.nlm.nih.gov/32307407
https://pubmed.ncbi.nlm.nih.gov/32307407
Autor:
S V Minaev, M. V. Metlina, G G Neznamov, S B Seredenin, Dorofeeva Oa, N Yu Ivashkina, T S Syunyakov, V A Martyanov
Publikováno v:
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 119(8)
To evaluate anxiolytic action of GB-115, a low-affinity blocker of central cholecystokinin receptors, used in tablets in a dose of 1 mg for the treatment of patients with anxiety disorders in order to determine effective dose, safety, tolerability an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75a417a4a6b55768d3970505a4cf7ec0
https://pubmed.ncbi.nlm.nih.gov/31626171
https://pubmed.ncbi.nlm.nih.gov/31626171
Autor:
V. K. Bochkarev, G. G. Neznamov
Publikováno v:
Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 118:53
To study the relationship between subjective evaluation (SE) of the effect of single test doses of benzodiazepine anxiolytic phenazepam and placebo and objective electroencephalography (EEG) characteristics in patients with anxiety disorders.Forty pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::733b139a796d4e95c3116de5d28bcb56
https://doi.org/10.17116/jnevro201811809153
https://doi.org/10.17116/jnevro201811809153
Autor:
Dorofeeva Oa, T. V. Kovalenok, M. V. Metlina, A. A. Chepelyuk, M. G. Vinogradova, G G Neznamov
Publikováno v:
Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 118:4
To study the relationship between cognitive functions and psychopathological disturbances in anxiety disorders.WAIS, the modified Witkin's Embedded figures test, a symptom scale (Yu.A. Aleksandrovsky et al. 1984) were administered to 111 patients, in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c81787313f681838e9c387605e1d6429
https://doi.org/10.17116/jnevro2018118314-9
https://doi.org/10.17116/jnevro2018118314-9
Publikováno v:
Eksperimental'naia i klinicheskaia farmakologiia. 77(12)
The effect of acute, 7-fold and 14-fold noopept (1 mg/kg/day) administration on the dynamics of anxiolitic and nootropic behavioral effects in cross-maze, as well as their correlations with NMDA- and BDZ-receptor density was studied in inbred mice st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8780c4ad50a4f638bf3c61953018357e
https://pubmed.ncbi.nlm.nih.gov/25739185
https://pubmed.ncbi.nlm.nih.gov/25739185
Publikováno v:
Eksperimental'naia i klinicheskaia farmakologiia. 76(9)
The influence of acute and long-term piracetam administration on the dynamics of rapid (non-specific, anxiolytic) and slow (specific, nootropic) behavioral drug effects, as well as on their interrelation with NMDA- and BDZ-receptors was studied in in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::02ffb6d4ca214eace37a7d4f3765a7dc
https://pubmed.ncbi.nlm.nih.gov/24432561
https://pubmed.ncbi.nlm.nih.gov/24432561
Autor:
R V, Shevchenko, A A, Litvin, G B, Kolyvanov, S S, Boĭko, V P, Zherdev, S Iu, Serebrova, N Iu, Ivashkina, G G, Neznamov, S A, Siuniakov
Publikováno v:
Eksperimental'naia i klinicheskaia farmakologiia. 76(6)
The pharmacokinetic study of a new original antipsychotic drug Dilept in healthy volunteers was performed. Volunteers received Dilept as single 20, 40 or 60 mg tablets. The parent drug in the human blood plasma was detected in low concentrations and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::386c8f18135fb686e2d4e9d40156a6d0
https://pubmed.ncbi.nlm.nih.gov/24003489
https://pubmed.ncbi.nlm.nih.gov/24003489